Clinical Trials on rrMM

Total 35 results

The Sixth Affiliated Hospital of Wenzhou Medical...
Zhejiang Qixin Biotech

Unknown

Integrin β7, BCMA, CS1, CD38 and CD138 as the Single or Compound Targets for the Fourth Genenation of CAR-T Cells

RRMM

China
Oncopeptides AB

Terminated

A PK, Safety and Tolerability Study of Peripheral and Central Infusion of Melflufen in RRMM Patients (PORT)

RRMM

Bulgaria, United States, Czechia, Hungary, Ukraine
Merck Sharp & Dohme LLC

Terminated

Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155/KEYNOTE-155)

rrCLL | rrMM | rrDLBCL
Genesis Pharma CNS & Specialty

Completed

Study to Assess Resource Utilization and Quality of Life of Patients With RRMS Treated With Tecfidera in Greece (FIDELITY)

RRMS

Greece
Takeda

Terminated

A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM)

Relapsed and/or Refractory Multiple Myeloma (RRMM)

United States, Canada
Janssen-Cilag Ltd.

Recruiting

A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials (REALiTEC)

Relapsed/Refractory Multiple Myeloma (RRMM)

Spain, France
Regeneron Pharmaceuticals

Recruiting

A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma (LINKER-MM3)

Relapsed Refractory Multiple Myeloma (RRMM)

United States, Korea, Republic of, Australia, Israel, Spain, United Kingdom, Poland, Taiwan, Singapore, France, Canada, Italy
Regeneron Pharmaceuticals

Active, not recruiting

Real-World Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma

Relapsed and Refractory Multiple Myeloma (RRMM)

United States
National Cancer Institute (NCI)

Recruiting

18F-Fluciclovine PET/CT in Multiple Myeloma

Multiple Myeloma | Relapsed and/or Refractory Multiple Myeloma (RRMM) | Newly Diagnosed Multiple Myeloma (NDMM)

United States
Novartis Pharmaceuticals

Completed

Optical Coherence Tomography (OCT) Trial in Multiple Sclerosis (OCTIMS)

Multiple Sclerosis | RRMS

Spain, Czechia, Germany, Australia, Italy, Switzerland, Denmark, United States, United Kingdom, Canada, Netherlands, Poland
Bayer

Completed

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment (BEACON)

Relapsing Remitting Multiple Sclerosis (RRMS)

China, Slovakia, France, Germany, Korea, Republic of, Saudi Arabia, Singapore, Sweden, Taiwan, Colombia, Czech Republic, Estonia, Italy, Jordan, Lebanon, Mexico, Slovenia, United Kingdom, Argentina, Bahrain, Egypt, United Arab Emirates and more
Novartis Pharmaceuticals

Completed

A 3-year Multi-center Study to Describe Changes of OCT Parameters Under Treatment With Gilenya® (PASSOS)

Relapsing Remitting Multiple Sclerosis RRMS

Germany, Switzerland
Novartis Pharmaceuticals

Terminated

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone (ASSESS)

Relapsing-remitting Multiple Sclerosis (RRMS)

United States, Canada, Mexico, Brazil, Puerto Rico, Argentina, Chile
GE Healthcare
Centre for Probe Development and Commercialization

Completed

Assess Safety, Bio-distribution, Radiation Dosimetry and Optimize the Imaging Protocol of GEH120714 (18F) Injection in Healthy Volunteers and Participants With Relapsing and Remitting Multiple Sclerosis (rrMS).

Relapsing-remitting Multiple Sclerosis (rrMS)

Canada
Novartis Pharmaceuticals

Completed

POC-MD MRI-based Trial in Relapsing-remitting Multiple Scler

Relapsing-remitting Multiple Sclerosis | RRMS

Russian Federation, Ukraine, Czech Republic
Biogen

Recruiting

A Study for Tysabri Participant Preference

Relapsing-Remitting Multiple Sclerosis (RRMS)

Germany
Bayer

Completed

BetaPlus Survey - Observational Study to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon® by Using Elements of the BetaPlus Program

Relapsing Remitting MS (RRMS) | Secondary Progressive MS (SPMS)

France, Germany, Korea, Republic of, Saudi Arabia, Spain, Taiwan, Czech Republic, Italy, Jordan, Lebanon, Turkey, Israel, Portugal, Netherlands, Iran, Islamic Republic of
Immunic AG

Active, not recruiting

MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS) (EMPhASIS)

Relapsing-Remitting Multiple Sclerosis (RRMS)

Poland, Bulgaria, Romania, Ukraine
Biogen
AbbVie

Terminated

Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab (SUSTAIN)

Relapsing-Remitting Multiple Sclerosis (RRMS)

Italy, United States, Canada, Germany, Puerto Rico
Biogen
Elan Pharmaceuticals

Completed

A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients (TIMER)

Relapsing Remitting Multiple Sclerosis (RRMS)

Belgium, Mexico, Poland, Romania, Saudi Arabia, Ukraine
EMD Serono
Pfizer

Completed

RNF and Betaseron® Tolerability Study (REFORMS)

Relapsing Remitting Multiple Sclerosis (RRMS)

United States
Bristol-Myers Squibb

Recruiting

A Study to Describe the Persistence With Ozanimod Treatment in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants (AppreZiate)

Relapsing-remitting Multiple Sclerosis (RRMS)

Spain
Biogen

Completed

Plegridy Satisfaction Study in Participants (PLATINUM)

Relapsing-Remitting Multiple Sclerosis (RRMS)

Italy
Polpharma Biologics S.A.

Completed

Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri® (Antelope)

Relapsing-Remitting Multiple Sclerosis (RRMS)

Belarus, Ukraine, Georgia, Croatia, Moldova, Republic of, Poland, Serbia
Cinnagen

Completed

Efficacy and Safety of Peginterferon Beta-1a (CinnaGen) in Participants With Relapsing Remitting Multiple Sclerosis

Relapsing Remitting Multiple Sclerosis (RRMS)

Iran, Islamic Republic of
Germans Trias i Pujol Hospital
Ministerio de Sanidad, Servicios Sociales e Igualdad

Completed

Phase I-II Clinical Trial With Autologous Bone Marrow Derived Mesenchymal Stem Cells for the Therapy of Multiple Sclerosis

Relapsing Remitting Multiple Sclerosis (RRMS)

Spain
Novartis Pharmaceuticals

Terminated

Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod (TOFIINGO)

Relapsing Remitting Multiple Sclerosis (RRMS)

Germany, Spain, Australia, Israel, Switzerland, Italy, Austria, Greece, Hungary, Czech Republic, Finland
Merck KGaA, Darmstadt, Germany
Smerud Medical Research International AS; Merck Serono Norway

Completed

A Scandinavian Non-interventional Study of Adherence to RebiSmart Administered Rebif New Formulation (RNF) Treatment in Relapsing Remitting Multiple Sclerosis (RRMS) Subjects (SCANSMART)

Relapsing Remitting Multiple Sclerosis (RRMS)

Norway
Icahn School of Medicine at Mount Sinai

Withdrawn

Sensation, Motion, and Quality of Life on Natalizumab and Off Natalizumab

Relapsing-remitting Multiple Sclerosis (RRMS)

United States
Biogen

Withdrawn

Brimonidine Tartrate for the Treatment of Injection Related Erythema (BRITE)

Relapsing-Remitting Multiple Sclerosis (RRMS)
Genmab

Recruiting

GEN3014 Safety Trial in Relapsed or Refractory Hematologic Malignancies

Acute Myeloid Leukemia (AML) | Diffuse Large B Cell Lymphoma (DLBCL) | Relapsed or Refractory Multiple Myeloma (RRMM)

United States, Korea, Republic of, Netherlands, Denmark, Australia, New Zealand, Poland, Spain, Sweden, Czechia, Malaysia, Greece, Moldova, Republic of, Georgia, Ukraine, France, Hungary, North Macedonia
Bayer

Completed

Portuguese Observational Survey to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon by Using Elements of the BetaPlus Program - Nurse Support, Auto-injectors (POR-BetaPlus)

Secondary Progressive Multiple Sclerosis (SPMS) | Relapsing Remitting Multiple Sclerosis (RRMS)

Portugal
Neuromed IRCCS
University of Rome Tor Vergata

Not yet recruiting

Effects of Ozanimod on Immune-mediated Mechanisms of Neurodegeneration in Multiple Sclerosis - a Preclinical Study

Healthy | Neuromyelitis Optica | Relapsing-Remitting Multiple Sclerosis (RRMS)

Italy
University Hospital, Basel, Switzerland
Swiss National Science Foundation

Recruiting

Imaging the Interplay Between Axonal Damage and Repair in Multiple Sclerosis (INsIDER)

Multiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)

Switzerland
Karyopharm Therapeutics Inc

Active, not recruiting

Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications

Acute Myeloid Leukemia (AML) | Metastatic Colorectal Cancer (mCRC) | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Relapsed/Refractory Multiple Myeloma (RRMM) | Higher-Risk Myelodysplastic Syndrome (HR-MDS) | Newly Diagnosed Intermediate/High-Risk MDS

United States, France, Canada, Spain, China

Clinical Trials on rrMM

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kenya

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations